Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

The decision to administer adjuvant chemotherapy in treatment of early invasive breast cancer (EBC) is often complex, particularly for hormone receptor-positive (HR+) diseases, and current guidelines often classify these patients in an intermediate-risk group. Several biomarkers are currently availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexandre, Marie, Maran-Gonzalez, Aurélie, Viala, Marie, Firmin, Nelly, D’Hondt, Véronique, Gutowski, Marian, Bourgier, Céline, Jacot, William, Guiu, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912012/
https://www.ncbi.nlm.nih.gov/pubmed/31849525
http://dx.doi.org/10.2147/CMAR.S221676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912012/
https://www.ncbi.nlm.nih.gov/pubmed/31849525
http://dx.doi.org/10.2147/CMAR.S221676

Ejemplares similares